- Home
- BDRX vs KTTA Comparison
BDRX vs KTTA Comparison
Compare BDRX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- KTTA
- Stock Information
- Founded
- BDRX 2000
- KTTA 2020
- Country
- BDRX United Kingdom
- KTTA United States
- Employees
- BDRX N/A
- KTTA N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- KTTA Health Care
- Exchange
- BDRX Nasdaq
- KTTA Nasdaq
- Market Cap
- BDRX 3.4M
- KTTA 3.5M
- IPO Year
- BDRX N/A
- KTTA 2021
- Fundamental
- Price
- BDRX $3.80
- KTTA $3.38
- Analyst Decision
- BDRX Strong Buy
- KTTA
- Analyst Count
- BDRX 1
- KTTA 0
- Target Price
- BDRX $200.00
- KTTA N/A
- AVG Volume (30 Days)
- BDRX 55.5K
- KTTA 29.8K
- Earning Date
- BDRX 11-26-2024
- KTTA 11-13-2024
- Dividend Yield
- BDRX N/A
- KTTA N/A
- EPS Growth
- BDRX N/A
- KTTA N/A
- EPS
- BDRX N/A
- KTTA N/A
- Revenue
- BDRX $104,895.00
- KTTA N/A
- Revenue This Year
- BDRX N/A
- KTTA N/A
- Revenue Next Year
- BDRX N/A
- KTTA N/A
- P/E Ratio
- BDRX N/A
- KTTA N/A
- Revenue Growth
- BDRX N/A
- KTTA N/A
- 52 Week Low
- BDRX $3.51
- KTTA $3.19
- 52 Week High
- BDRX $220.25
- KTTA $17.40
- Technical
- Relative Strength Index (RSI)
- BDRX 29.07
- KTTA 38.62
- Support Level
- BDRX $4.70
- KTTA $3.20
- Resistance Level
- BDRX $5.58
- KTTA $3.46
- Average True Range (ATR)
- BDRX 0.48
- KTTA 0.35
- MACD
- BDRX -0.08
- KTTA -0.01
- Stochastic Oscillator
- BDRX 9.03
- KTTA 16.38
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.